CoChat

FXR silencing in human colon cancer by DNA methylation and KRAS signaling

Open access
Bailey, Ann M., Zhan, Le, Maru, Dipen, Shureiqi, Imad, Pickering, Curtis R., Kiriakova, Galina, Izzo, Julie, He, Nan, Wei, Caimiao, Baladandayuthapani, Veerabhadran, Liang, Han, Kopetz, Scott, Powis, Garth, Guo, Grace L. · 2014 · American Journal of Physiology-Gastrointestinal and Liver Physiology
Cited by 85

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Farnesoid X receptor (FXR) is a bile acid nuclear receptor described through mouse knockout studies as a tumor suppressor for the development of colon adenocarcinomas. This study investigates the regulation of FXR in the development of human colon cancer. We used immunohistochemistry of FXR in normal tissue ( n = 238), polyps ( n = 32), and adenocarcinomas, staged I–IV ( n = 43, 39, 68, and 9), of the colon; RT-quantitative PCR, reverse-phase protein array, and Western blot analysis in 15 colon cancer cell lines; NR1H4 promoter methylation and mRNA expression in colon cancer samples from The Cancer Genome Atlas; DNA methyltransferase inhibition; methyl-DNA immunoprecipitation (MeDIP); bisulfite sequencing; and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) knockdown assessment to investigate FXR regulation in colon cancer development. Immunohistochemistry and quantitative RT-PCR revealed that expression and function of FXR was reduced in precancerous lesions and silenced in a majority of stage I-IV tumors. FXR expression negatively correlated with phosphatidylinositol-4, 5-bisphosphate 3 kinase signaling and the epithelial-to-mesenchymal transition. The NR1H4 promoter is methylated in ∼12% colon cancer The Cancer Genome Atlas samples, and methylation patterns segregate with tumor subtypes. Inhibition of DNA methylation and KRAS silencing both increased FXR expression. FXR expression is decreased early in human colon cancer progression, and both DNA methylation and KRAS signaling may be contributing factors to FXR silencing. FXR potentially suppresses epithelial-to-mesenchymal transition and other oncogenic signaling cascades, and restoration of FXR activity, by blocking silencing mechanisms or increasing residual FXR activity, represents promising therapeutic options for the treatment of colon cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpgi.00234.2013

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 85

Metadata

Authors
Bailey, A. M., Zhan, L., Maru, D., Shureiqi, I., Pickering, C. R., Kiriakova, G., Izzo, J., He, N., Wei, C., Baladandayuthapani, V., Liang, H., Kopetz, S., Powis, G., & Guo, G. L.
Venue
American Journal of Physiology-Gastrointestinal and Liver Physiology
Published
2014-01-01
Volume
306
Issue
1
Pages
G48-G58
ISSN
  • 0193-1857 (ISSN-L)
  • 1522-1547
OpenAlex
W2100399645
Cited by
85
References
8
FWCI
1.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FXR silencing in human colon cancer by DNA methylation and KRAS signaling. https://app.cochat.ai/papers/10.1152/ajpgi.00234.2013
The paper
Bailey, A. M., Zhan, L., Maru, D., Shureiqi, I., Pickering, C. R., Kiriakova, G., Izzo, J., He, N., Wei, C., Baladandayuthapani, V., Liang, H., Kopetz, S., Powis, G., & Guo, G. L. (2014). FXR silencing in human colon cancer by DNA methylation and KRAS signaling. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00234.2013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.